Recently, it was shown that the activation of intestinal PXR signaling induced dyslipidemia and intestinal cholesterol accumulation [11], while activation of hepatic PXR signaling was sufficient to promote hypercholesterolemia and hepatic lipid accumulation [12]. This evidence concerns the gene NR1I2 and metabolic syndrome.